3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
7
Sarcoma
5
Melanoma
5
Lymphoma, Non-Hodgkin
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
4
Endometrial Neoplasms
4
Carcinoma, Hepatocellular
4
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myeloid, Acute
3
Kidney Neoplasms
3
Glioblastoma
3
Squamous Cell Carcinoma of Head and Neck
2
Rhabdomyosarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Lymphoma, Mantle-Cell
2
Liver Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Fallopian Tube Neoplasms
2
Congenital Abnormalities
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Interventions
Gemcitabine
83
Cisplatin
59
pembrolizumab
28
Paclitaxel
21
Nivolumab
21
Carboplatin
21
Cystectomy
20
Docetaxel
18
durvalumab
17
atezolizumab
17
Magnetic Resonance Spectroscopy
16
Specimen Handling
15
Radiotherapy
14
avelumab
13
Mitomycin
13
Sunitinib
12
Doxorubicin
12
Methotrexate
11
Fluorouracil
11
Vinblastine
10
Filgrastim
7
BCG Vaccine
7
Sorafenib
6
Ipilimumab
6
Immunoglobulin G
6
Disulfides
6
Biopsy
6
enfortumab vedotin
5
cabozantinib
5
Trastuzumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urinary Bladder Neoplasms
×
temsirolimus
×
Clear all
NCT01827943
2021-05-06
VESTOR
Institut Bergonié
Phase 2
Completed
54 enrolled
8 charts